FindTrial
Sign In

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02090127
Enrollment
Unknown
Registered
2014-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2015-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mullerian Mixed Tumor of Ovary

Brief summary

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Detailed description

This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.

Interventions

DRUGficlatuzumab

humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator

Sponsors

AVEO Pharmaceuticals, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* Per original P05538 protocol

Exclusion criteria

* Per original P05538 protocol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026